Crinetics Pharmaceuticals, Inc. Revenue from Contract with Customer, Including Assessed Tax
Crinetics Pharmaceuticals, Inc. (CRNX) reported Revenue from Contract with Customer, Including Assessed Tax of $1.04 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2025-02-27
- Crinetics Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $1.04M, a 74.11% decline from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $4.01M, a 15.28% decline from fiscal 2022.
- Crinetics Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $4.74M, a 339.42% increase from fiscal 2021.
- Crinetics Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $1.08M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|
| 2024-12-31 | $1.04M 10-K · filed 2025-02-27 |
| 2023-12-31 | $4.01M 10-K · filed 2025-02-27 |
| 2022-12-31 | $4.74M 10-K · filed 2025-02-27 |
| 2021-12-31 | $1.08M 10-K · filed 2024-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-30 |